SCHEMBL5924416

SCHEMBL5924416

CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3n[nH]c4ncccc34)cs2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 18/20 0.75
CYP3A4 P08684 16/20 0.75
PRKACA P17612 2/20 0.66
ROCK2 O75116 1/20 0.66
CYP2D6 P10635 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
MAPK1 P28482 2/20 0.57
CIT O14578 1/20 0.57
MAP3K7 O43318 1/20 0.57
JAK2 O60674 1/20 0.57
RPS6KA5 O75582 1/20 0.57
RPS6KA4 O75676 1/20 0.57
PRKCG P05129 1/20 0.57
PRKCB P05771 1/20 0.57
CCNA2 P20248 1/20 0.57
RPS6KB1 P23443 1/20 0.57
CDK2 P24941 1/20 0.57
FLT3 P36888 1/20 0.57
GSK3B P49841 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5924446 0.88 ROCK1 (0.64) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL5924544 0.86 ROCK1 (0.56) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL13887795 0.85 ROCK1 (1.00) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL5924430 0.84 ROCK1 (0.58) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL14493836 0.80 ROCK1 (0.79) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL439602 0.80 ROCK1 (0.81) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL439598 0.79 ROCK1 (1.00) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL439574 0.79 ROCK1 (1.00) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL437294 0.79 ROCK1 (1.00) ROCK1CYP3A4PRKACAROCK2CYP2D6
SCHEMBL5265935 0.76 ROCK1 (0.79) ROCK1CYP3A4PRKACAROCK2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122185-A1 Bicyclic inhibitors of Rho kinase VERTEX PHARMACEUTICALS INCORPORATED 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122185-A1 Bicyclic inhibitors of Rho kinase ROCK1, ROCK2, RHOA ROCK1 1/4885CYP3A4 3909/4885PRKACA 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.